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Table 1
Cumulative incidence of infection at 1 year with 95% CI
UCB MUD MMUD p-value
Bacterial 71% (66-75%) 63% (59-66%) 66% (60-71%) .01
Fungal 15% (12-18%) 8% (7-11%) 13% (9-17%) .002
Virus (all) 69% (65-73%) 44% (41-47%) 54% (48-60%) P<.0001
Table 2
Rate of viral infections per patient per year, stratiﬁed by graft source
Virus UCB MUD MMUD p-value
CMV 0.783 0.411 0.598 <.001
Adenovirus 0.099 0.034 0.056 .008
EBV 0.096 0.091 0.152 .04
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fungal infections (p ¼ .52); however, UCB recipients had
signiﬁcantly more viral infections compared to MMUD (p
<.0001).The rate (infections per patient per year) of CMV
reactivation/disease and adenoviral infections was higher in
UCB recipients; MMUD had a higher rate of EBV reactivation
(Table 2). Infection as a cause of death was similar among the
three graft sources at 1 year (41%, 31%, and 38% for UCB,
MUD, andMMUD respectively). Overall survival at 1 year was
50% (46 e 55%), 69% (65 e 72%), and 58% (52 e 64%) for UCB,
MUD, and MMUD respectively (p<.0001) and this difference
was driven by higher treatment related mortality (TRM) as
relapse was similar across the groups. The survival was
slightly higher with MMUD compared to UCB (p<.04). In
conclusion, 1) The incidences of bacterial, fungal, and
particularly viral infections are high after alternative donor
transplant; 2) Infections are a major cause of death in the
ﬁrst year after alternative donor transplant; 3) The incidence
of infection as cause of death was similar among the graft
sources; 4) Viral infections are higher in recipients of UCB
compared to MMUD. Future directions will focus on pre-
ventative techniques and predictors for infection, particu-
larly for viral infections.Table
Results of univariate analyses
Graft type N 100 d
survival, %
(95% CI)
Median total
LOS in ﬁrst
100 d
Median days
alive out of
hospital in
ﬁrst 100 d
Ped MA HCT
Single UCB 219 88 (83-92) 47* 50*
Double UCB 80 85 (76-92) 44 55
8/8 URD BM 69 94 (88-98) 40 60
Adult MA HCT
Single UCB 65 74 (63-84)* 40* 52*
Double UCB 146 79 (72-85) 40 55
7/8 URD BM 42 76 (62-88) 32 64
7/8 URD PBSC 126 79 (72-86) 29 67
8/8 URD BM 92 91 (85-96) 29 69
8/8 URD PBSC 297 90 (86-93) 25 75
Adult RIC HCT
Single UCB 16 75 (74-85)* 31* 65*
Double UCB 188 80 (74-85) 33 64
7/8 URD PBSC 77 87 (79-94) 20 79
8/8 URD PBSC 160 93 (89-97) 21 79
*P<.05 for group comparison104
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Use of alternative donors (unrelated umbilical cord blood
(UCB), haploidentical family members, mismatched unre-
lated donors (URD)) allows patients without HLA matched
sibling or unrelated donors to proceed to HCT. Several
retrospective studies show comparable survival outcomes
among different alternative graft sources, but the relative
cost of HCT by graft source has not been well studied. We
compared total hospital length of stay, which included
initial hospitalization and readmissions (LOS) in the ﬁrst
100 days as a surrogate for short-term costs and resource
utilization, in a cohort of alternative donor HCT recipients
reported to the CIBMTR from 2008-2011. Patients were
included if they had received HCT in the US for acute
leukemia in 1st or 2nd CR using UCB or HLA-mismatched
URD. We also included HLA-matched URD HCT recipients
for comparison; there were too few haploidentical HCT
reported to the CIBMTR during this time period to allow
comparisons. The cohort was restricted to patients
receiving similar conditioning and GVHD prophylaxis reg-
imens. We analyzed the 1577 eligible patients in three
separate groups: pediatric HCT after myeloablative (MA)
conditioning (age 18 y, N¼368), adult HCT after MA
conditioning (N¼768) and adult HCT after reduced in-
tensity conditioning (RIC, N¼441).Within each of these
three groups, we compared match/donor categories with
sufﬁcient number of patients. There was no difference in
HCT comorbidity index scores by graft sources in any
group. Table 1 shows 100 day overall survival and the
median total LOS in the ﬁrst 100 days after HCT. To account
for the differential rates of 100 day mortality in some co-
horts, we also describe median days alive out of hospital in
ﬁrst 100 days. In univariate analyses, single and double
UCB HCT recipients had longer LOS than patients receiving
other graft sources, but there was no difference in LOS
between single and double UCB recipients. In conclusion;
LOS in the ﬁrst 100 days varies substantially by graft
source, with LOS being greater for UCB HCT recipients. LOS
is similar between single and double UCB. Ongoing
multivariate analyses will consider LOS among graft sour-
ces while adjusting for patient and disease related vari-
ables. Our data have implications for resource allocation
for alternative donor HCT.
